These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of Ca2+-antagonistic vasodilators, diltiazem, nifedipine, perhexiline and verapamil, on platelet aggregation in vitro.
    Author: Ono H, Kimura M.
    Journal: Arzneimittelforschung; 1981; 31(7):1131-4. PubMed ID: 7196762.
    Abstract:
    Ca2+-Antagonistic vasodilators, diltiazem, nifedipine, perhexiline and verapamil, showed inhibitory activity on platelet aggregation in human platelet-rich plasma (PRP) induced with ADP, adrenaline and collagen. Preincubation of PRP with one of the drugs effectively prevented the aggregation induced by ADP, ID50s being 2.1 x 10(-4), 3.5 x 10(-5), 3.4 x 10(-5) and 2.3 x 10(-4) g/ml for diltiazem, nifedipine, perhexiline and verapamil, respectively. Nifedipine and perhexiline were equipotent and about 10 times as potent as diltiazem and verapamil. In addition, PRP maximally aggregated with 9.1 mumol/l ADP was disaggregated by administration of any of these drugs. The mechanism of action was considered to be Ca2+-antagonism because, with the exception of perhexiline, the potency ratio of the anti-aggregating activity had a close resemblance to that of the vasodilator activity of these drugs previously reported in the literature. Perhexiline showed the most potent anti-aggregating activity but has been reported to be the least potent vasodilator among the Ca2+-antagonists studied. This further studies are necessary to elucidate the mechanism of perhexiline's inhibition of platelet aggregation.
    [Abstract] [Full Text] [Related] [New Search]